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1. Patient Orientation in Health Services Research 
 
1.1 Objectives of Health Services Research 
 
Health services research is the systematic study of the delivery of health care 
products and services to individuals and the population under conditions of routine 
care and how this affects access to health care, quality and cost of health care as 
well as health outcomes (IQWIG 2017; Lohr and Steinwachs 2002). 
 
The target of health services research lies with the health care system, its institutional, 
professional and organisational structure and the provision of services. Compared 
with public health, health services research has a similar analytical frame, the patient 
and population perspective, and shares the overarching goals, namely the prevention 
of disease, the prolonging of life and the promotion of health. Unlike public health, 
health services research does not extend to societal action and responsibilities for 
health and well-being, and is therefore more confined (Dragano et al. 2016; Schrappe 
and Pfaff 2011). 
 
To improve health care, health services research evaluates the quality and 
effectiveness of services, interventions or models of care in real-world settings. In a 
multi-disciplinary tradition, processes of decision-making, practice and organisational 
culture and the impact of commercial interests and financial resources and incentives 
are examined (Boyer and Lutfey 2010). Importantly, the complexity of interventions 
and their implementation into ‘active’ contexts is addressed (Geraedts et al. 2017; 
Greenhalgh and Papoutsi 2018; Schrappe and Pfaff 2016). 
 
Baumann et al. (2016) point to value-driven perceptions of quality in health care, 
embedded in the societal and political discourse on health care needs and the level 
of care provision that is appropriate and justified. Adopting this view, the applied 
stance of health services research in Germany, with its aim to inform policy-makers 
and to promote evidence-based health care provision, bears significant weight. It 
makes patient orientation of pivotal importance vis-à-vis economic and political 





1.2 Strengthening Patient Orientation in Health Services Research 
 
Patient-centredness, as one of six proclaimed aims of health care – the others being 
safety, effectiveness, timeliness, efficiency and equity – were described in a landmark 
publication by the US Institute of Medicine (IOM) in 2001: 
‘…the patient’s experience of illness and health care and […] the systems that work 
[…] to meet the individual patients’ needs. […] Providing care that is respectful of, 
and responsive to, individual patient preferences, needs and values, and ensuring 
that patient values guide all clinical decisions’ (IOM 2001, p. 48). 
 
Further attributes of this rather all-encompassing concept originate from an 
influential publication commissioned by the Picker Institute in 2008, the ‘Patient-
Centered Care Improvement Guide’: 
‘Ultimately, it is about a collective commitment to a set of beliefs about the way 
patients will be cared for, how family will be treated, how leadership will support 
staff, and how staff will nurture each other and themselves’ (Frampton et al. 2008, 
p. 20). 
 
Patient-centredness as an aim and concept underlines changes in the understanding 
of the roles of patients and health care providers towards joint responsibility and 
collaborative decision-making. It implies power-sharing on behalf of physicians in 
terms of recognising and empowering patients as ‘experts in their own illness’ (Mead 
and Bower 2000), whilst holding on to the professional authority to grant access to 
health care services and treatments. Greenhalgh conceptualises clinical decision-
making as i) attending to evidence-based knowledge; ii) co-constructing a healing or 
coping narrative with the patient; and iii) using experiential clinical knowledge to gain 
judgement of the individual situation (Greenhalgh 2013). 
 
On a health system level, patient-centredness calls for ongoing evaluation and quality 
improvement efforts, including the use of patient-reported outcome measures 
(PROMs) (Santana and Feeny 2014). The defining feature of patient-reported 
outcomes (PROs), compared with other types of health outcomes such as laboratory 
results, is that they are conditions known only to the patients themselves and 
obtained directly from them (Patrick, Guyatt, and Acquandro 2008). PROs provide 
standardised measures of health and well-being that are essential to guide health 




outcomes relevant to patients in relation to the effectiveness of a single intervention 
or treatment. Underlying this definition is evidence about the relative importance of a 
range of outcomes from the perspective of patients’ needs (Schunemann et al. 2019; 
Yordanov, Dechartres, and Ravaud 2018; Zhang et al. 2017). 
 
PROMs can be broadly classified as i) condition-specific (measuring, for example, the 
number and severity of symptoms of a specific condition, outcomes of specific 
procedures) and ii) generic health-related quality of life (HRQL) instruments that 
assess a broad range of physical and psychosocial domains. Drawing on the Wilson 
and Cleary model of HRQL and the model underpinning the International 
Classification of Functioning, Disability and Health (ICF), Valderas and Alonso 
differentiate between psychometric, econometric and clinimetric PRO instruments 
measuring i) symptoms, ii) functional status, iii) general health perceptions (e.g. ‘how 
would you rate your overall health’), iv) HRQL and v) other health-related constructs 
(e.g. satisfaction with health care processes, self-management) (Valderas and 
Alonso 2008). HRQL can be seen as the most encompassing concept, bundling 
together the subjective and dynamic perceptions with regard to one’s health or 
disease status (Bakas et al. 2012; Ferrans et al. 2005). 
 
Two developments in the measurement of health outcomes should be mentioned: 
first, there is the acknowledgement of the impact of management of therapeutic 
regimes and self-management on HRQL (Bakas et al. 2012). With a view to evaluating 
the processes of clinical care, the importance of instruments assessing the quality of 
communication, the degree of patient activation and shared decision-making and the 
extent of self-management and satisfaction (of both patients and clinicians) have 
been highlighted (Santana and Feeny 2014). Second, to allow for more individualised 
measures, particularly in clinical practice and the evaluation of services, more flexible 
measures (e.g. goal attainment scales) have been developed as well as item banks 
and strategies for adaptive testing (Rose et al. 2014; Turner-Stokes et al. 2012). Both 
should guide assessment of HRQL towards a more comprehensive approach, e.g. in 
intervention research. 
 
PROMs play an increasing role in public reporting and performance measurement, 
such as in the UK Quality and Outcome Framework (QOF), and in clinical practice 




2016; Van Der Wees et al. 2014). This may help towards critically examining the match 
between therapeutic decisions, patients’ health goals, timely access, integrated care 
pathways and evidence of under- and overutilisation, driven by commercial interests 
and by health disparities linked to age, gender, ethnicity and socio-economic status 
(SES) (Boyer and Lutfey 2010; Calvert et al. 2019; Olde Rikkert et al. 2018; Van Der 
Wees et al. 2014). 
 
As primary or secondary outcomes in research studies, both trial-based and 
observational, PROMs describe disease burden and are used in evaluations of 
interventions and services with the aim of informing decisions regarding clinical 
recommendations, service development and coverage. The GRADE Evidence to 
Decision frameworks seek to facilitate the assessment of the quality of evidence, i.e. 
the quality of instruments, and the translation of research evidence to specific clinical 
contexts (Alonso-Coello et al. 2016). To advance the integration of the quantitative 
stance of PROMs with evidence on patient experiences from qualitative studies, the 
Cochrane Qualitative and Implementation Methods group has developed guidance 
(Harden et al. 2018). 
 
In summary, research to strengthen patient orientation in health services research 
aims to facilitate improvements in patient-centred care in real-life settings. In this 
chapter, patient orientation in health services research has been described as 
movement towards joint responsibility and collaborative decision-making in health 
care. Health care services are shifting to primarily manage long-term conditions. 
Health service research should therefore focus on the role of patients’ self-
management. HRQL detriments attributable to symptom burden and loss of 
functional status in chronic illness are of particular importance. Against this 
background, Anderson et al. call for the following research agenda for health service 
research to improve patient-centred care: 
 
 
(1) prioritise research into chronic and often progressive illness, with reference to 
its impact on the global burden of disease; 
(2) focus upon patient-reported outcome measures to assist patients and 






(3) develop interventions that help patients to gain positive control over aspects 
of their illness and/or their responses to them and evaluate their effectiveness 
(Anderson et al. 2015). 
Before moving on to address some of these challenges, drawing on PROMs using 
the example of my own research in diabetes care, I will briefly outline 
conceptualisations of the co-production of health by patients in the management 
of chronic illnesses. 
 
1.3 Patient Self-management in Chronic Illness 
 
Chronic diseases are the leading causes of death across OECD countries (OECD 
2019). In Germany, 43.8% of people aged 16 years or older were reported in Eurostat’s 
European Health Interview Survey (EHIS-2) in 2018 to be living with a long-standing 
illness or health problem (Eurostat 2019). The prevalence of multimorbidity, the 
coexistence of several chronic diseases, is very high in the older population (Fabbri et 
al. 2015). Hypertension, allergies, arthrosis and diabetes have the highest prevalence 
among chronic diseases across European countries (Fehr et al. 2017). Chronic 
diseases account for the majority of health care utilisation and expenditure. They can 
be characterised by multicausal, non-linear and intertwined symptoms, which create 
illness burden and affect multiple domains of life (Anderson et al. 2015). 
 
In chronic illness, patient self-management is a daily, interactive and dynamic 
process, which constitutes living with the illness, supported by family, community and 
health care professionals (Bodenheimer, Wagner, and Grumbach 2002; Richard and 
Shea 2011). Corbin and Strauss perceived three dimensions of self-management: 
medical management, behavioural management (e.g. adapting lifestyles, activating 
resources) and emotional work (cited by Schulman-Green et al. (2012)). As Hinder 
and Greenhalgh point out, people spend only a fraction of their time with health 
professionals (Hinder and Greenhalgh 2012). Social–cultural and material 
constraints that shape individual choices are often more influential than medical 
advice, in view of both behavioural and lifestyle changes, but also whether and how 
recommended treatment regimens are implemented in daily routines (Barry, 





In the cumulative complexity model, Shippee conceptualises patients’ experiences 
with care and self-management by distinguishing between illness burden (e.g. 
symptoms, management and limitations through symptoms) and treatment burden 
(e.g. appointments, monitoring) (Shippee et al. 2012). Both affect patients’ capacity 
to access health care services, to organise support, to perform self-care and self-
management tasks and, ultimately, impact upon health outcomes. Chronic illness 
forces patients to perform ‘adaptive work’ to develop responses to new illness or 
treatment-related issues or limitations as they arise, often in an unpredictable 
manner. Chronic care interventions and services need to go beyond traditional patient 
education but should activate the patient and increase or facilitate self-care and self-
efficacy, even if patients had initially hoped for quick ‘medical fixes’ to their problems 
(Anderson et al. 2015; Holman and Lorig 2004; Michie, Miles, and Weinman 2003). 
This may include reducing treatment burden in patients and carers overwhelmed by 
chronic care, as captured in the concept of ‘minimally disruptive medicine’ (Boehmer 
et al. 2016a,b; Demain et al. 2015). 
 
1.4 Outline of the Summary 
 
In the following, diabetes will serve as an example of a chronic disease and front-line 
health care problem that requires multiple patient-oriented interventions based on 
evidence from health services research. This summary appraises the contribution of 
the accompanying original research publications in two related fields of study: i) the 
impact of diabetes on HRQL and ii) the quality of diabetes care with focus on patient-
reported indicators and self- management. Chapter 2 provides a brief overview of the 
societal burden and of challenges in the prevention and treatment of type 2 diabetes. 
Chapter 3 maps the individual disease burden by measuring the impact of diabetes 
on HRQL, drawing on a series of studies using cross-sectional and longitudinal data 
from a pooled analysis of population-based survey studies in Germany. Chapter 4 
assesses care processes and outcomes with data from population-based cohort 
studies conducted in the Augsburg region of southern Germany (KORA–Cooperative 
Research in the Region of Augsburg).The concluding chapter 5 gives an outlook on 







2. Diabetes as a Chronic Disease and Health Care Problem 
 
According to the International Diabetes Federation (IDF), 8.8% of the world population 
have been diagnosed with type 2 diabetes, in addition to an almost equal number of 
people with impaired glucose tolerance that precedes the development of the disease 
(Cefalu et al. 2016). For Germany, data from five population-based regional studies 
and one nationwide study within the Diabetes Collaborative Research of 
Epidemiologic Studies (DIAB-CORE), conducted between 1997 and 2006, provided 
prevalence and incidence estimates of self- reported type 2 diabetes mellitus. 
Standardised to the German population, these were 8.6% (8.1–9.1%) for the regional 
studies and 8.2% (7.3–9.2%) for the nationwide survey (Schipf et al. 2012). Incidence 
rates calculated by drawing on the respective follow-up studies, conducted between 
1997 and 2010, were 11.8/1000 person-years (95%CI 10.8–12.9), with a mean follow-
up of 2.2–7.1 years (Schipf et al. 2014). The incidence increased with age and was 
higher in men than in women. Incident type 2 diabetes was strongly associated with 
anthropometric markers that reflect abdominal obesity (Hartwig et al. 2016). 
 
Regional differences within Germany were shown for both prevalence and incidence, 
highest in the east and lowest in the south of Germany, indicating a southwest-to-
northeast gradient. It was shown that area deprivation plays an important role in 
increasing the risk of developing diabetes, in addition to the individual SES and 
independent of risk factors such as sex, age, BMI, physical activity, smoking status 
and alcohol consumption (Maier et al. 2013; Maier et al. 2014). Comparing data from 
the northeast (SHIP-TREND) and south of Germany (KORA F4) in adults between 35 
and 79 years of age, the age- and sex-standardised prevalence of undiagnosed type 
2 diabetes and prediabetes followed the same pattern of regional differences 
(Tamayo et al. 2014a). Prediabetes rates were estimated to be 43.1% (95% CI 40.9–
45.3) in SHIP-TREND and 30.1% (95% CI 28.4–31.7) in KORA F4; rates of unknown 
diabetes were estimated to be 7.1% (95% CI 5.9–8.2) in SHIP-TREND and 3.9% (95% 
CI 3.2–4.6) in KORA F4. These regional differences persisted after adjustment for 
known risk factors such as BMI, physical activity, smoking or limited education. Thus, 
environmental and setting-based prevention strategies are of equal importance in 






The high and increasing prevalence and the high incidence of associated 
complications and comorbid conditions make diabetes a prime case to assess HRQL 
as a measure of disease burden in chronic diseases. Generic instruments to measure 
HRQL are most widely used because they allow for comparison within and between 
populations and people with medical conditions (Bayliss et al. 2017). 
 
Patient-important outcomes in diabetes can be conceptualised as mortality rates and 
morbidity, leading to detriments in HRQL and functional status (Gandhi et al. 
2008).Type 2 diabetes poses a particular risk of decline in physical health, with its 
relative position similar to that of congestive heart failure or chronic respiratory 
disease (Sprangers et al. 2000). Health burden in diabetes also stems from a high 
prevalence of comorbid conditions. A large population-based sample of people with 
type 2 diabetes in the US showed that 44.1% had one chronic condition in addition to 
diabetes, 18.4% had two additional conditions and 11.9% had three or more additional 
chronic conditions, recorded in 2 years after the diabetes diagnosis (Weir et al. 2016). 
The likelihood of conditions that have a pathophysiological link to diabetes, such as 
cardio-metabolic risk factors or cardiovascular disease (CVD), is two or three times 
higher in people with diabetes, according to a German survey study among adults 
aged 50 years and older (Du et al. 2013). Estimations of the burden of diabetes in 
patients with coronary heart disease in a population-based study in Augsburg, 
Germany, showed reduced HRQL (measured with the EQ-5D 0.82 (95% CI 0.80–0.84)) 
at baseline and increased mortality (HR 1.68 (95% CI 1.17–2.40)) over a period of 4.1 
years (Laxy et al. 2015). The magnitude of the adverse HRQL effects has important 
implications for public health efforts to lower the risk of developing the disease. 
 
Quality improvement in diabetes care over the last 30 years has led to a 
standardisation of physician-led care and treatment decisions by practice guidelines 
and evidence-based medicine. A patient-centred treatment approach is endorsed as 
a central aim by the American Diabetes Association and the European Association for 
the Study of Diabetes (Inzucchi et al. 2012). Increasingly, clinical guidelines are 
replaced by complex sets of clinical decision rules, in particular with regard to 
glycated haemoglobin (HbA1c) levels, e.g. 6.0–6.5% (42–48 mmol/mol); <7.0% (53 
mmol/mol); 7.5–8.0% (58–64 mmol/mol), considered as appropriate treatment aims 
for subgroups of patients, such as considering multimorbidity (Inzucchi et al. 2015). 




control and multifactorial risk reduction in type 2 diabetes were introduced in 2003 
(Stark et al. 2009). Intermediate endpoints that indicate disease progression and thus 
increased risk in terms of mortality and comorbidity are often used in assessing 
quality of care and treatment effectiveness in diabetes care. 
 
Diabetes is associated with high health care costs. Ulrich et al. calculated the overall 
direct medical costs such as outpatient services, hospital care, rehabilitation and 
medication to be 1.81 (95%CI 1.56–2.11) times higher in people with diabetes (Ulrich 
et al. 2016). Relative excess costs were particularly high in younger (<50 years) age 
groups (Kähm et al. 2019). Weir et al. (2016) found an average number of 20.7 
physician visits (SD 21) during the 2 years following diabetes diagnosis with a mean 
of 8.5 (SD6.4) different physicians in a US- based study. A diabetes diagnosis also 
bears significant monetary costs depending on the coverage of medical services and 
drugs in the respective health care system, as well as time costs (Claessen et al. 2013; 
Icks et al. 2013a,b). 
 
At all stages of the disease, treatment is coupled with a substantial number of self- 
management tasks such as measuring blood glucose, monitoring of feet and weight, 
medication, regular attendance at check-ups as well as lifestyle changes to adopt 
healthy eating habits and increase physical activity (Nefs et al. 2012). Diabetes self-
management can be effective in improving short-term process measures (patient 
knowledge, accuracy of self-monitoring of blood glucose, HbA1c and cholesterol 
screenings and dietary habits) and health outcomes (‘intermediate outcomes’, i.e. 
reductions in HbA1c, lipids, blood pressure, medication use and weight gain) 
(Captieux et al. 2018). Lower health service utilisation and costs during one follow-up 
year have been shown (for example, by Strawbridge et al. 2017) in beneficiaries 
receiving self-management training in a large population-based sample in the US. 
Evidence remains inconclusive on the attributes of effective self-management 
support (i.e. education, therapeutic relationship), its antecedents (i.e. health literacy, 
personal capacities and life circumstances) and consequences (i.e. improved 









In the following summary of my research and the accompanying original research 
publications, the overarching theme is disease burden and quality of care in diabetes 
care, with special focus on PRO-based measurements and developments in Germany. 
This work aims to contribute in a twofold manner: accumulating evidence on 
differences in the magnitude and impact of the disease burden in relation to diabetes 
treatment, age and gender as well as longitudinal disease trajectories is highly 
relevant for health care decision-making in view of different subgroups of patients. 
Conceptualising PRO-based integrated measurements of quality of care, drawing on 
population-based data, is needed to inform and monitor the increasing use of such 
indicators in routine data and health system-triggered performance measurement. 
With these data, it was possible to focus in particular on care processes in view of 







3. Health-related Quality of Life in Diabetes in a Cross-
sectional and Longitudinal Perspective 
 
As part of a BMBF (German Federal Ministry of Education and Research)-funded 
project (DIAB-CORE), data from several regional and one national population-based 
cohort studies in Germany were pooled to compare population values of HRQL 
measured with the SF-36/12 in people with and without type 2 diabetes in both cross-
sectional and longitudinal perspectives (Schunk et al. 2012a,b; Schunk et al. 2017). 
The SF-36/12 is a generic instrument to measure HRQL (Ware at al. 1996). It is a 
profile instrument and yields summary scores for physical and mental health: the 
physical component summary (PCS) and the mental component summary (MCS). 
The SF-36/12 was used in the 12-item version, correspondingly calculating the PCS-
12 and the MCS-12. 
 
 
3.1 Health-related Quality of Life Disease Burden 
 
The cross-sectional analysis of five regional and one national studies, conducted 
between 1997 and 2006, with a pooled sample of n=9579, shows that type 2 diabetes 
is associated with lower PCS-12 scores by 4.1points, which equals the decline in PCS-
12 between people aged 45 years and 65 years (Figure1) (Schunk et al. 2012a,b). 
Differences between people with and without diabetes in MCS-12 scores were smaller 
(–2.5 points) and only significant in women. Age is statistically significantly 
associated with both PCS-12 and MCS-12 scores for subjects with and without type 
2 diabetes. As shown in Figure 1, greater age is associated with lower PCS-12 scores, 
but increased MCS-12 scores. Differences between subjects with and without type 2 
diabetes decrease slightly with age, but there is no statistically significant interaction 
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Figure1: PCS-12 and MCS-12 differences between people with and without 
diabetes by age group (adjusted for sex and study effects, lines are connected to 
improve graphical representation) (adapted from Fig 1 in Schunk et al. 2012b) 
 
Further analyses explored the impact of comorbidities, socio-economic variables, 
obesity and health behaviour on the magnitude of detriment in HRQL in those with 
diabetes, dividing them according to their treatment with or without insulin. 
Controlling for age, education, income and health behaviour, the PCS-12 detriment is 
much more pronounced in people with insulin-treated diabetes (–3.92 (95% CI –5.12; 
–2.72), compared with people without insulin treatment (–1.88 (95%CI –2.66; –1.10). 
This is also the case for women with regard to MCS-12 (–3.22 (95%CI –5.53; –0.92) 
(insulin treated); –1.29 (95%CI –2.78; 0.19n.s.) (non-insulin treated) (Schunk et al. 
2012b). Results from former studies were inconsistent as to whether insulin 
treatment is independently associated with lower HRQL after adjustment for 
comorbidities. Our results add empirical evidence supporting the view that patients 
receiving insulin treatment have lower HRQL after adjustment for comorbidities. 
Myocardial infarction, stroke and hypertension were independently associated with a 
detriment in PCS-12 and MCS-12. Therefore, we could not show what Hunger et al. 
(2011) had found with data from the KORA-Age study of 4565 Germans aged 65 years 
or older, namely the joint impact of diabetes and coronary events on HRQL to be much 
stronger than their independent effects, indicating the importance of CVD risk factor 
management in patients with diabetes. However, this may result from the use of a 
different instrument to assess HRQL, the EQ-5D. The pooled data indicated sex 




but also regarding the association with body weight, as measured by the BMI. These 
will be addressed in the following. 
 
3.2 Gender Differences and Treatment Effects 
 
When exploring the impact of diabetes on HRQL measured with the SF-12, we 
consistently found significantly lower PCS-12 scores for both women and men. 
However, the effects on MCS-12 could only be shown in women. Comparisons of 
HRQL across different types of diabetes treatment have rarely been undertaken, 
although treatment types reflect different stages of the disease, differences in the risk 
of tolerability issues and in the complexity of treatment regimes. By dividing patients 
with diabetes into subgroups with different treatment regimens (insulin/no insulin), 
gender differences prevailed. In Figure 2, the pooled summary scores are shown for 
women and men separately; scores for women are consistently lower than those for 
men (Schunk et al. 2012b). The diabetes effect on PCS-12 increases for patients of 
both sexes with insulin therapy. For women only, this can be shown for MCS-12 scores 
as well. This result was replicated in an analysis of the pooled DIAB-CORE data with 
a diabetes-only sample (n=846), dividing treatment groups even further (Schunk et al. 
2015a). Using subgroups with different treatment regimens (no antidiabetic 
medication, oral antidiabetic medication (OAD), combination of OAD and insulin, 
insulin only), women and men have similar PCS-12 mean scores in the no-medication 
and insulin groups. Men tend to have higher scores than women in the OAD and 
combination treatment groups, but these differences proved not to be significant. 
However, with regard to MCS-12 scores, differences between women and men 
associated with treatment were significant (P-value >0.0001). Compared with men 
receiving OAD and combination treatment, women had lower MCS-12 scores (49.0 
vs. 53.3 for OAD treatment, 47.0 vs. 54.0 for combination treatment). MCS-12 scores 
exhibit detriments for women in the oral, combination or insulin treatment groups (–








Figure 2: Differences in HRQL by diabetes status, insulin treatment and gender, 
adjusted for age and study effects (adapted from Fig 2 in Schunk et al. 2012b) 
 
We also analysed SF-12 single items after dichotomising the item coding (Schunk et 
al. 2015a). Again, women scored lower than men across all treatment groups 
involving medication. Differences between women and men were strongest in the 
OAD and combination treatment groups and reached significance for 5 of the 12 
items, such as mental health (feeling downhearted and depressed), social functioning 
and emotional role limitation (did activities less carefully). One tentative interpretation 
of the observed differences between women and men is that women may react more 
strongly with a sense of loss of perceived control, e.g. due to failure of dietary 
appraisal, when diet- and lifestyle-based treatment has proven to be ineffective and 
OAD treatment is started as the first-line option. Laxy et al. drew attention to a gender-
specific pattern in the impact of weight change on HRQL in the KORA S4/F4 cohort, 
with a positive association between weight change an MCS-12 in women, mainly 
driven by questions referring to the domains ‘mental health’ and ‘emotional role 
limitation’ (Laxy et al. 2014a). Overall, there are only a very few studies that describe 
gender differences in symptom presentation, treatment and control in diabetes 
patients. More research is needed to clarify the impact of body weight-sensitive 
chronic illnesses such as diabetes on women to derive gender-specific strategies to 






3.3 Longitudinal Analysis 
 
Longitudinal analysis of three regional studies and one national study (pooled 
n=5367) over a mean observation time of 8.7 years pointed to significantly larger 
declines in mean PCS-12 and MCS-12 scores among people with prevalent and 
incident diabetes, compared with those without diabetes at both baseline and follow-
up (Schunk et al. 2017). Mean score change in PCS-12 per observation year, adjusted 
for age and study, as shown in Figure 3, is –0.22 (95%CI –0.26; –0.18) points, –0.38 
(95%CI –0.50; –0.25) points and –0.53 (95%CI –0.67; –0.39) points for the groups 
without diabetes, with incident diabetes and prevalent diabetes respectively. For 
MCS-12, the corresponding numbers are –0.06 (95% CI –0.10; 0.01), –0.18 (95%CI 
–0.33; –0.04) and –0.43 (95%CI –0.60; –0.27). This indicates a much faster decline 
in PCS-12 in people with prevalent diabetes (about 5 points over 10 years) compared 
with a decrease of less than 2 points (for both those without diabetes and, at a lower 
starting point, those with prevalent diabetes), which we identified in cross-sectional 
analysis. Unlike in cross-sectional analysis, a decline in MCS-12 over time for both 
women and men with prevalent diabetes was evident in longitudinal analysis. 
 
Figure 3: Mean score change (PCS-12, MCS-12) per observation year, adjusted for 
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Significantly larger mean changes over time in both PCS-12 and MCS-12 scores 
persisted in people with prevalent diabetes at baseline compared with the group 
without diabetes, when additionally controlling for socio-economic differences and 
lifestyle variables. In contrast, declines in mean PCS-12 and MCS-12 scores between 
incident diabetes and no diabetes groups did not reach significance or were explained 
in models adjusting for covariables. 
 
This confirmed the results from Hunger et al. (2014), looking at longitudinal changes 
in HRQL for the transition from normal glucose tolerance via prediabetes to diabetes. 
Using data from two cross-sectional population-based KORA survey studies (over 7 
years from 1999–2001 to 2006–2008), people with normal glucose tolerance (NGT) 
at baseline who had progressed to diabetes at follow-up experienced a greater loss 
in mean PCS-12 scores than people with persistent NGT (–7.44 (95% CI –13.09 ; –
1.79) points). However, the decline that was shown for the MCS-12 scores or for both 
PCS-12 and MCS-12 scores in people progressing from NGT to prediabetes or from 
prediabetes to diabetes did not reach significance (Hunger et al. 2014). 
 
In summary, our pooled analysis of individual data critically augments the sparse data 
on HRQL in people with diabetes in Germany with population-based estimates from 
both regional and national cohort studies. Obtaining reliable estimates for different 
subgroups, such as between women and men or treatment groups, is urgently needed 
to investigate the effects of the socio-demographic and clinical characteristics of 
diabetes. For the first time, this pooled data set provides sample sizes sufficiently 
large for such key analyses. Our findings point to a significant detriment in PCS-12 
scores for people with diabetes, compared with those without diabetes, extending to 
a detriment in MCS-12 scores for women only. Underlining the importance of cohort 
studies, longitudinal analysis revealed a much larger diabetes-associated loss of 
HRQL than estimated using cross-sectional data. Therefore, efforts to improve 
diabetes management, including evidence-based treatment and advice on self-
management, are key to alleviate the diabetes burden on afflicted patients. Our 
assessment of the status quo and time trends in the quality of diabetes care will be 





4. Self-management and Quality of Diabetes Care 
 
Health care systems increasingly attempt to deal with chronic diseases by 
standardising treatment and clinical practice, such as using treatment guidelines and 
the introduction of structured care processes, i.e. DMPs. Within the framework of 
such programmes, evidence-based protocols for treatment, care coordination and 
patient education have been introduced. Diabetes was one of the first diseases for 
which such programmes were established in Germany, starting in 2003. Diabetes care 
and burden of disease have been examined in KORA cohort studies since 1997/1998, 
drawing on the KORA diabetes questionnaire, a standardised and field-tested tool to 
assess patient-related information on diabetes care. Together with other parts of the 
survey, conveying information on socio-demographics, medical examinations, 
medication and health-related behaviour, we were thus able to test the relationship 
between guideline-defined diabetes processes and health outcomes over time. 
 
In an early study, using data from cross-sectional KORA surveys conducted at 
intervals in 1997–1998 and 2004–2005, we analysed several indicators of diabetes 
care with a focus on self-management. Robust improvements in participation in 
educational programmes, knowledge about the disease, physical activity and 
metabolic outcomes were found (Schunk et al. 2009). Drawing on this evidence, 
diabetes care arguably moved forward, albeit from very low levels (Icks et al. 2006). 
We extended the analysis in a subsequent study, comparing cross-sectional KORA 
survey data from 1999–2000, 2004–2005 and 2006–2008. Improvements were 
found only with regard to the frequency of at least one foot examination in the past 
12 months (37.5% vs. 45.7% vs. 55.1%) and an increase in the intake of medication 
related to cardiovascular comorbidities or risk factors (anti-hypertensive medications, 
lipid-lowering medication and platelet aggregation inhibitors) (as shown in Figure 4) 







Figure 4: Comparison of time trends under consideration of DMP participation  
(Figure adapted from Fig 2 in Schunk et al. 2011; Stark et al. 2011)2 
 
This may be related to the introduction of diabetes DMPs in 2003. One study 
compared people in the KORA survey of 2006–2008 who were enrolled in diabetes 
DMPs with those who were not enrolled (Stark et al. 2011). Summarising indicators 
of quality of care, people enrolled in DMPs reported appropriate health care processes 
more often (eyes, feet, cholesterol examination in the last 12 months) and reached 
certain therapeutic goals more frequently (BP<140/90 mmHg 64% vs. 80%). In 
general, DMPs may have caused spillover effects that increased the quality of care 
for all patients with diabetes. 
 
Despite these encouraging findings, other studies drawing on data from this period 
highlighted shortfalls in the treatment of people with diabetes. For example, a study 
of pooled data from population-based studies across Germany conducted between 
1997 and 2006 identified untreated or insufficiently treated elevated blood pressure 
targets (>140/90mmHg) in 64% of n=1287 participants with type 2 diabetes mellitus 
(T2DM). Lipid management was found to be insufficient, with a prevalence of 
dyslipidaemia (total cholesterol/HDL ratio of ≥5) of 40% (Rückert et al. 2012). 
Following up these findings in a subsample with longitudinal data, blood pressure 
values were still higher than target levels in about 50% of people with diabetes after 
                                                     
2Translated by permission from Springer Nature: Springer Nature Bundesgesundheitsblatt – Gesundheitsforschung 
– Gesundheitsschutz (Verbesserungen in der Versorgung von Patienten mit Typ-2-Diabetes? Schunk M, Stark R, 





6–7 years on average (Rückert et al. 2015). This indicates that treatment regimens to 
control cardiovascular risk factors in diabetes care are not optimally adjusted, despite 
their beneficial effects in terms of a reduction in cardiovascular morbidity and 
mortality. 
 
Using cross-sectional KORA data pooled from two surveys conducted in 2004–05 and 
2006–08, it was shown that people with diabetes were well supported by health 
professionals, as indicated by the number of routine medical examinations, diabetes 
education and multi-professional care, engaged in higher levels of self-monitoring 
activities, such as foot care or blood glucose measurement, and revealed higher 
adherence to professional recommendations concerning diet (Schunk et al. 2015b). 
Encouraging patient participation, e.g. by shared decision-making styles, in diabetes 
treatment increases patients’ understanding and motivation to follow up on 
recommended activities, as shown by Heisler et al. (2009) in a US-based study. 
However, in our study, the intensity of care processes, treatment satisfaction or the 
perceived quality of the patient–physician relationship were not associated with 
higher levels of adherence regarding other recommendations, such as medication, 
foot care and physical activity, or with health behaviour itself. Physical activity levels 
were very low, with only 15% reporting regular physical exercise. 
 
A later analysis, widened to include KORA survey data from 2013–2014, found no 
changes in self-management and few changes in physician-delivered care (increase 
in reported annual HbA1c examinations from 2000 (29%) to 2007 (53%) to 2014 
(72%)). On the other hand, a substantially increased proportion of people reached 
targeted goals for glycaemic control, blood pressure control and HDL cholesterol 
(Laxy et al. 2016). Observed improvements in this study were larger when comparing 
2007 with 2000 than when comparing 2014 with 2007. Over a period of 10 years, from 
2004/5 to 2014, the percentage of survey participants with T2DM who reported not 
having received advice on diet or physical exercise or ever participating in patient 
education has remained unchanged at around 50% (Laxy et al. 2016; Schunk et al. 
2015b). 
 
Patient time spent on self-management, drawing on data from the KORA diabetes 
questionnaire in the 2013–2014 survey, has been calculated to amount to ~2.5 h (149 




estimated to be needed, if recommendations, as established in guidelines, are 
adhered to (Russell, Suh, and Safford 2005), and also significantly less than reported 
in a US study from 2000/1, where patients reported spending a median of 48 min/day 
(Safford et al. 2005). 
 
In the analysis of KORA data, the different types of self-management activities were 
divided into disease-specific clinical activities such as measuring blood glucose and 
blood pressure, taking medication and foot and skin care, and lifestyle-related 
activities such as exercise, shopping and cooking. The resulting time expenditures 
are shown in Figure 5. People with insulin or oral anti-hyperglycaemic drug treatment, 
better diabetes education, HbA1c 48 to <58 mmol/mol (6.5% to <7.5%), lower quality 
of life as well as an overall healthier lifestyle and more social support (being married 
or living with a partner) spent more time on self-management activities (Icks et al. 
2019). These findings support the hypothesis that lower capacity may disrupt the 




Figure 5: Time spent on diabetes-related self-management activities in KORA 
survey participants (light grey: mean time on average across all respondents; dark grey: 
mean time on average across all of those who endorsed time for the respective activity) 
(Icks et al. 2019, Figure 2b)3 
                                                     
3Reprinted by permission from John Wiley and Sons Diabetes Medicine (Time spent on self-management by people 
with diabetes: results from the population-based KORA survey in Germany. Icks A, Haastert B, Arend W, Konein J, 




The importance of strengthening self-management in patients with T2DM was 
underlined in a further study using data from a KORA survey in 1997–1998, which 
estimated the effect of self-management on mortality. Quantifying the extent of self-
management using a published index (Arnold-Wörner et al. 2008) at baseline, it was 
shown in a 12-year mortality follow-up of a sample of 340 people with diabetes that 
people with strong self-management behaviour had a 39% reduced risk of dying from 
all causes (HR 0.61 (0.40–0.91)) within the observation period, controlling for 
intermediate clinical outcomes (e.g. microalbuminuria, polyneuropathy, LDL 
cholesterol, blood pressure) (Laxy et al. 2014b). 
 
Overall, empirical evidence on the association between care processes and clinical 
outcomes remains inconclusive. More research should be directed to understand the 
associations between self-management, health literacy and care processes, as well 
as their effect on clinical outcomes. Following the evidence that population-based 
KORA data illustrate for the south of Germany, it can be assumed that improvements 
have flattened out. This prompts an urgent call for renewed efforts to increase the 
frequency of care processes and to strengthen patients’ support from health 
professionals. 
 
As monitoring of care processes and outcomes needs to continue with population-
based data as well as clinical samples, we must pay heightened attention to 
inequalities in diabetes management. Patient groups with low individual SES and 
residential area deprivation receive lower levels of care (Grintsova, Maier, and Mielck 
2014; Maier 2017). Regional differences in diabetes treatment, e.g. in the use of new 
anti- hyperglycaemic drugs, have been shown to be significant after adjustment for 
SES and regional deprivation and are still largely unexplained (Bächle et al. 2018; 
Tamayo et al. 2014b). Often overlooked populations such as people in 
institutionalised care, e.g. suffering from dementia, need further research (Sinclair et 
al. 2018). Claims data from the AOK Bavaria Statutory Health Insurance for the years 
2005–2006 revealed very low levels of diabetes-related medical examinations in 
people with dementia, which decreased even further after nursing home placement 






5. Conclusions and Outlook 
 
Starting from the proposition to strengthen patient orientation in health services 
research, this summary of research findings in the field of diabetes care adds to this 
aim in several ways. We were able to show that diabetes-associated loss of HRQL is 
much greater in a longitudinal perspective than assumed from cross-sectional 
analysis. Drawing on results from our studies with the SF-12, the decreased diabetes-
related HRQL in women is associated with diabetes treatment regimens (Schunk et 
al. 2015a). 
 
Population-based data on HRQL, such as presented herein, drawing on pooled data 
from regional and one national cohort studies in Germany, are essential to estimate 
disease burden and to derive priorities for health care policy. Uniquely, these survey 
data extend the measurement of disease burden to people not accessing health 
services. Although previous studies mostly relied on cross-sectional data, we were 
able to better elucidate the true disease burden of type 2 diabetes by analysing 
longitudinal data, where individual trajectories of prevalent and incident cases can be 
followed. Further research should focus on longitudinal studies, augmenting generic 
with diabetes- and treatment-specific instruments. 
 
The high prevalence of comorbidities, such as CVDs and neuropathy, and late-stage 
complications impose a heavy physical and psychological burden on people with type 
2 diabetes. With our findings, we were able to point to a halting of earlier 
improvements in the last 5–10 years and still very low levels of patient activation 
(Schunk et al. 2017). As there are hopes for interventions such as lifestyle 
modifications and pharmacotherapy to prevent diabetes in high-risk individuals, our 
studies point to the fact that current diabetes care in Germany needs to improve, both 
in adhering to guideline-defined processes but also in engaging the patient in disease 
management (Laxy et al. 2016; Schunk et al. 2009; Schunk et al. 2011). 
 
The KORA diabetes questionnaire offers valuable data on patient-reported process 
and outcome indicators that go beyond specific clinical interventions, thereby 
integrating components that are guided by the patients themselves, such as 




their long-standing operation as a cohort study starting 30 years ago with multiple 
follow-up studies, the KORA data allow cross-sectional and longitudinal analyses. 
Because of their important role in contextualising findings from clinical studies and 
secondary data analyses, such as from routinely collected data, the use of research-
orientated data drawn from population-based cohort studies with multiple waves of 
data should be expanded. Generally, research should routinely analyse effect 
mediation and effect modification by gender, such as a recent analysis from Du et al. 
(2019). More studies should elicit patient preferences, drawing on psychometric 
instruments, for different health outcomes, e.g. on the benefits and harms of 
treatments in subgroups of patients, to further our understanding of patient-important 
outcomes (Ashman et al. 2019). PROM instruments that may be sensitive to gender 
differences should be prioritised in future research. 
 
More research is needed to strengthen the understanding of which factors are most 
important for enhancing self-management and clinical outcomes, including patient 
expectations, attachment styles, self-efficacy and professionals’ patient-centredness 
(Serrano et al. 2016; Strawbridge et al. 2017), and studies will have to draw on a 
combination of both quantitative and qualitative approaches (Mead and Bower 2000; 
Nutting et al. 2007). 
 
On a health system level, further efforts are needed to incentivise quality of care 
improvements drawing on patient-important outcome measures (Du et al. 2015; 
Glasgow, Peoples, and Scotland 2008; Greenhalgh et al. 2018). Service development 
should aim at organisational attributes that impact patient-centred health care 
delivery with a focus on how they help patients to gain positive control over aspects 
of their illness, e.g. more integrated forms of services ensuring access to and 
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